Leading the way to a new standard of care for gastrointestinal disease

Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the clinical drug candidate vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.

Phathom has assembled a leading team of seasoned gastrointestinal and pharmaceutical industry experts with proven experience developing and commercializing highly innovative therapies.

Executive Leadership Team

Board of Directors 


Phathom has completed a $90 million private financing with leading life science institutional investors and a $50 million term loan facility with Silicon Valley Bank.